Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HER2 B Cell Peptide Vaccine in Locally Advanced HER2 Positive Breast Cancer
NCT06949410Phase 1Recruiting
- Start
- Jan 2027
- Primary completion
- Dec 2029
- Modality
- Peptides, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial in HER2-positive breast cancer. Primary endpoints: Evaluation of safety and toxicity by NCI common toxicity criteria 5.0 and Immune Response. Planned start Jan 2027; status: recruiting.
02
Conditions
HER2-positive breast cancer
Beyond the preview
Go deeper on NCT06949410.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06949410.